United States Upsher Tender

Upsher-Smith Laboratories LLC Upsher-Smith announced that it has completed the acquisition of Tosymra sumatriptan Nasal Spray 10 mg and Zembrace SymTouch sumatriptan Injection 3 mg from Dr. Reddys Laboratories Limited. The products were previously commercialized through Dr. Reddys wholly owned subsidiary Promius Pharma LLC. Both medications are indicated for the acute treatment of migraine with or without aura in adults.More than thirty-six million Americans suffer from migraines and Upsher-Smith is proud to be diversifying our portfolio with two products that can bring pain relief to a significant number of patients suffering from acute migraine said Rusty Field President and CEO Upsher-Smith. We will be working diligently to ensure the smooth delivery of Zembrace SymTouch to patients and to prepare for the launch of Tosymra which we expect to take place toward the end of 2019. The addition of Tosymra and Zembrace SymTouch rounds out Upsher-Smiths migraine product portfolio. The Company currently offers Qudexy XR topiramate Extended-Release Capsules a once-daily treatment for use in the prevention of migraine headache in adults and adolescents 12 years of age and older. Ballard Spahr LLP served as the Companys legal counsel on this transaction.